高级检索
当前位置: 首页 > 详情页

A whole slide image-based risk score predicts prognosis and postmastectomy radiotherapy benefit in triple negative breast cancer patients

文献详情

资源类型:
Pubmed体系:
机构: [1]Department of Pathology, Institute of Clinical Pathology, Key Laboratory of Transplant Engineering and Immunology (NHFPC), Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, 610041, China. [2]Image Processing and Parallel Computing Laboratory, School of Computer Science and Software Engineering, Southwest Petroleum University, Chengdu, 610500, China. [3]School of Computer Science and Engineering, University of Electronic Science and Technology of China, Xiyuan Ave, Chengdu, 611731, China. [4]Department of Oncology, The Third Affiliated Hospital of Chengdu Medical College, Pidu District People's Hospital, Chengdu, 611730, China. [5]Institute for Breast Health Medicine, Cancer Center, Breast Center, West China Hospital, Sichuan University, No. 37 Guoxue Lane, Wuhou District, Chengdu, 610041, Sichuan Province, China.District, Chengdu, 610041, Sichuan Province, China.
出处:

关键词: Triple-negative breast cancer Postmastectomy radiotherapy Whole slide image XGBoost Prognosis

摘要:
There are few tools support postmastectomy radiotherapy (PMRT) decisions for triple-negative breast cancer (TNBC) patients. This study aimed to develop a whole slide image (WSI)-based risk score to identify PMRT beneficiaries. We analyzed 608 TNBC patients treated at West China Hospital, Sichuan University (WCH) and 182 patients from The Cancer Genome Atlas (TCGA), diagnosed between 2011 and 2019. Utilizing features extracted from hematoxylin and eosin-stained WSI and clinicopathological characteristics, an image score and a clinicopathological score for each patient were computed via eXtreme Gradient Boosting, combined into a comprehensive risk score. Multivariate Cox proportional hazards regression analyses revealed a higher image score strongly associated with worse 5-year invasive disease-free survival (iDFS) (HR = 8.80, P < 0.001), overall survival (OS) (HR = 9.02, P < 0.001), and locoregional recurrence-free survival (LRFS) (HR = 8.39, P = 0.003). The integrated risk score outperformed clinicopathological score in prognostic accuracy, as evidenced by the area under the curve (WCH validation cohort, iDFS: 0.805 vs. 0.756; OS: 0.874 vs. 0.807; LRFS: 0.957 vs. 0.870; TCGA cohort, iDFS: 0.683 vs. 0.598; OS: 0.685 vs. 0.617). Importantly, PMRT significantly improved OS in "high-risk" patients identified by the risk score, but not in "low-risk" patients in both WCH and TCGA cohorts. These findings suggest that the WSI-based risk score shows promise as a tool for prognostic assessment and guiding PMRT decision-making in TNBC patients.© 2025. The Author(s).

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
大类 | 3 区 综合性期刊
小类 | 3 区 综合性期刊
最新[2025]版:
大类 | 3 区 综合性期刊
小类 | 3 区 综合性期刊
第一作者:
第一作者机构: [1]Department of Pathology, Institute of Clinical Pathology, Key Laboratory of Transplant Engineering and Immunology (NHFPC), Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, 610041, China.
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:65780 今日访问量:0 总访问量:5151 更新日期:2025-12-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号